BR112017003263A2 - anticorpos anti-vasa, e métodos de produção e utilização dos mesmos - Google Patents

anticorpos anti-vasa, e métodos de produção e utilização dos mesmos

Info

Publication number
BR112017003263A2
BR112017003263A2 BR112017003263A BR112017003263A BR112017003263A2 BR 112017003263 A2 BR112017003263 A2 BR 112017003263A2 BR 112017003263 A BR112017003263 A BR 112017003263A BR 112017003263 A BR112017003263 A BR 112017003263A BR 112017003263 A2 BR112017003263 A2 BR 112017003263A2
Authority
BR
Brazil
Prior art keywords
vasa
mabs
methods
production
antibodies
Prior art date
Application number
BR112017003263A
Other languages
English (en)
Inventor
Zhang Bo
T Weaver David
Original Assignee
Ovascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovascience Inc filed Critical Ovascience Inc
Publication of BR112017003263A2 publication Critical patent/BR112017003263A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04013—RNA helicase (3.6.4.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a anticorpos (mabs) anti-vasa, particularmente mabs humanizados que ligam especificamente a vasa com alta afinidade, são descritas. as sequências de aminoácidos das cdrs das cadeias leves e das cadeias pesadas, bem como sequências de consenso para estas cdrs, destes mabs anti-vasa são fornecidas. a descrição também fornece moléculas de ácido nucleico codificando os mabs anti-vasa, vetores de expressão, células hospedeiras, métodos para produzir os mabs anti-vasa, e métodos para expressar os mabs anti-vasa. finalmente, são fornecidos métodos de uso dos mabs anti-vasa para isolar e/ou purificar células expressando vasa.
BR112017003263A 2014-09-16 2015-09-16 anticorpos anti-vasa, e métodos de produção e utilização dos mesmos BR112017003263A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051130P 2014-09-16 2014-09-16
US201462089054P 2014-12-08 2014-12-08
PCT/US2015/050449 WO2016044436A2 (en) 2014-09-16 2015-09-16 Anti-vasa antibodies, and methods of production and use thereof

Publications (1)

Publication Number Publication Date
BR112017003263A2 true BR112017003263A2 (pt) 2017-11-28

Family

ID=55454121

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017003263A BR112017003263A2 (pt) 2014-09-16 2015-09-16 anticorpos anti-vasa, e métodos de produção e utilização dos mesmos

Country Status (26)

Country Link
US (4) US9403913B2 (pt)
EP (1) EP3194448A4 (pt)
JP (2) JP2017532953A (pt)
KR (1) KR20170056521A (pt)
CN (1) CN106573985A (pt)
AP (1) AP2017009758A0 (pt)
AU (1) AU2015317813B2 (pt)
BR (1) BR112017003263A2 (pt)
CA (1) CA2959179A1 (pt)
CL (1) CL2017000402A1 (pt)
CO (1) CO2017001724A2 (pt)
CR (1) CR20170067A (pt)
DO (1) DOP2017000050A (pt)
EA (1) EA201790236A1 (pt)
EC (1) ECSP17011262A (pt)
GT (1) GT201700036A (pt)
IL (1) IL250451A0 (pt)
MX (1) MX358243B (pt)
NI (1) NI201700022A (pt)
PE (1) PE20170667A1 (pt)
PH (1) PH12017500309A1 (pt)
SG (1) SG11201701016WA (pt)
SV (1) SV2017005393A (pt)
TN (1) TN2017000066A1 (pt)
TW (1) TW201619194A (pt)
WO (1) WO2016044436A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710645A2 (pt) 2006-04-07 2012-03-20 The Procter & Gamble Company Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
AU2015317813B2 (en) * 2014-09-16 2018-04-05 Ovascience, Inc. Anti-VASA antibodies, and methods of production and use thereof
SG10201912556VA (en) 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
KR20220098003A (ko) * 2019-11-11 2022-07-08 벤더르빌트 유니버시티 한타바이러스에 대한 인간 모노클로날 항체 및 이의 사용 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039518A1 (en) * 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
EP1233978A4 (en) * 1999-11-18 2003-07-23 Brigham & Womens Hospital COMPOSITIONS AND METHODS FOR IMPROVED DIAGNOSIS AND TREATMENT OF GERM CELL TUMORS
US6875854B1 (en) * 1999-11-18 2005-04-05 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
CA2897658A1 (en) 2004-05-17 2005-12-22 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
US7955846B2 (en) 2004-05-17 2011-06-07 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
EP2314317A3 (en) * 2004-07-09 2011-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
US20090061485A1 (en) * 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
US20110244485A1 (en) * 2008-09-25 2011-10-06 National University Corporation Tokyo University Of Marine Science And Technology Anti-tuna vasa antibody
KR20110099762A (ko) * 2008-12-26 2011-09-08 고쿠리츠다이가쿠호우진 도쿄다이가쿠 항ｌｇｒ７항체를 사용하는 암의 진단 및 치료
DK2462161T3 (en) * 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
EP2697365A4 (en) 2011-04-14 2014-07-23 Gen Hospital Corp COMPOSITIONS AND METHODS FOR AUTOLOGOUS ENERGY TRANSMISSION IN MITOCHONDRIAL GLAND LINES
EA201490050A1 (ru) * 2011-06-29 2014-07-30 Зе Дженерэл Хоспитэл Корпорейшн Композиции и способы повышения биоэнергетического состояния женских зародышевых клеток
US9428575B2 (en) * 2012-12-31 2016-08-30 Development Center For Biotechnology Anti-granulysin antibodies and methods of use thereof
AU2015317813B2 (en) * 2014-09-16 2018-04-05 Ovascience, Inc. Anti-VASA antibodies, and methods of production and use thereof
AU2016206945A1 (en) * 2015-01-13 2017-08-10 President And Fellows Of Harvard College Purification of germ stem cells by targeting MRP9

Also Published As

Publication number Publication date
IL250451A0 (en) 2017-03-30
TW201619194A (zh) 2016-06-01
DOP2017000050A (es) 2018-04-15
CA2959179A1 (en) 2016-03-24
PH12017500309A1 (en) 2017-07-10
US9403913B2 (en) 2016-08-02
AU2015317813A1 (en) 2017-03-02
SG11201701016WA (en) 2017-03-30
JP2018148915A (ja) 2018-09-27
MX358243B (es) 2018-08-10
SV2017005393A (es) 2017-06-07
US20160075797A1 (en) 2016-03-17
ECSP17011262A (es) 2017-05-31
AU2015317813B2 (en) 2018-04-05
EP3194448A4 (en) 2018-03-14
KR20170056521A (ko) 2017-05-23
WO2016044436A2 (en) 2016-03-24
US20180155445A1 (en) 2018-06-07
EA201790236A1 (ru) 2017-11-30
CL2017000402A1 (es) 2017-11-03
US20170107299A1 (en) 2017-04-20
MX2017002390A (es) 2017-07-28
EP3194448A2 (en) 2017-07-26
CN106573985A (zh) 2017-04-19
US20160311929A1 (en) 2016-10-27
CR20170067A (es) 2017-05-10
WO2016044436A3 (en) 2016-06-09
JP2017532953A (ja) 2017-11-09
TN2017000066A1 (en) 2018-07-04
PE20170667A1 (es) 2017-06-06
NI201700022A (es) 2017-05-04
AP2017009758A0 (en) 2017-02-28
CO2017001724A2 (es) 2017-07-19
US9567404B2 (en) 2017-02-14
GT201700036A (es) 2018-12-19

Similar Documents

Publication Publication Date Title
BR112017003263A2 (pt) anticorpos anti-vasa, e métodos de produção e utilização dos mesmos
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
BR112018006547A2 (pt) anticorpos de pd-1 e usos dos mesmos
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
EA201492101A1 (ru) Антитела против fcrn
EA201591814A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ Fc
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
PH12015501651B1 (en) Antibody constructs for cdh19 and cd3
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
EA201690992A1 (ru) Антитела, специфичные к fcrn
MY197221A (en) Anti-pcsk9 antibody and use thereof
CO2020004200A2 (es) Anticuerpo monoclonal anti-il-5rα
SA517390221B1 (ar) Igf-1r الجسم المضاد لـ واستخدامه في تشخيص سرطان
BR112017006736A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]